Dolby Laboratories (DLB)
(Real Time Quote from BATS)
$71.53 USD
-1.15 (-1.58%)
Updated Sep 19, 2024 11:42 AM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
Income Statements
Fiscal Year end for Dolby Laboratories falls in the month of September.
All items in Millions except EPS data.
9/30/23 | 9/30/22 | 9/30/21 | 9/30/20 | 9/30/19 | |
---|---|---|---|---|---|
Sales | 1,300 | 1,254 | 1,281 | 1,162 | 1,242 |
Cost Of Goods | 153 | 141 | 130 | 147 | 161 |
Gross Profit | 1,147 | 1,112 | 1,151 | 1,015 | 1,081 |
Selling & Adminstrative & Depr. & Amort Expenses | 931 | 906 | 807 | 797 | 824 |
Income After Depreciation & Amortization | 216 | 207 | 344 | 219 | 257 |
Non-Operating Income | 34 | 9 | 11 | 21 | 25 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | 250 | 215 | 355 | 240 | 282 |
Income Taxes | 48 | 31 | 37 | 8 | 27 |
Minority Interest | 1 | 0 | 8 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 202 | 184 | 318 | 232 | 256 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | 201 | 184 | 310 | 231 | 255 |
Depreciation Footnote | 9/30/23 | 9/30/22 | 9/30/21 | 9/30/20 | 9/30/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 310 | 312 | 459 | 310 | 343 |
Depreciation & Amortization (Cash Flow) | 95 | 105 | 114 | 92 | 85 |
Income After Depreciation & Amortization | 216 | 207 | 344 | 219 | 257 |
Earnings Per Share Data | 9/30/23 | 9/30/22 | 9/30/21 | 9/30/20 | 9/30/19 |
---|---|---|---|---|---|
Average Shares | 97.73 | 101.98 | 104.62 | 102.94 | 104.57 |
Diluted EPS Before Non-Recurring Items | 2.60 | 2.24 | 3.06 | 2.30 | 2.44 |
Diluted Net EPS (GAAP) | 2.05 | 1.81 | 2.97 | 2.25 | 2.44 |
Fiscal Year end for Dolby Laboratories falls in the month of September.
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 288.82 | 364.52 | 315.57 | 290.56 | 298.37 |
Cost Of Goods | 35.66 | 38.78 | 32.06 | 35.55 | 41.52 |
Gross Profit | 253.16 | 325.75 | 283.51 | 255.01 | 256.86 |
SG&A, R&D, and Dept/Amort Expenses | 216.37 | 216.78 | 217.29 | 258.51 | 240.92 |
Income After SG&A, R&D, and Dept/Amort Expenses | 36.79 | 108.97 | 66.22 | -3.50 | 15.94 |
Non-Operating Income | 13.38 | 12.78 | 14.61 | 12.37 | 7.94 |
Interest Expense | 0.00 | 0.00 | 0.00 | -0.16 | 0.11 |
Pretax Income | 50.16 | 121.75 | 80.83 | 9.03 | 23.76 |
Income Taxes | 10.51 | 23.53 | 13.25 | -0.88 | 7.35 |
Minority Interest | 1.21 | 0.38 | 0.60 | 0.72 | 0.01 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | 39.66 | 98.21 | 67.58 | 9.91 | 16.41 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | 38.44 | 97.83 | 66.98 | 9.19 | 16.40 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 96.96 | 96.86 | 97.44 | 97.68 | 97.46 |
Diluted EPS Before Non-Recurring Items | 0.47 | 1.01 | 0.76 | 0.39 | 0.32 |
Diluted Net EPS (GAAP) | 0.40 | 1.01 | 0.69 | 0.08 | 0.17 |